SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-012517
Filing Date
2022-08-08
Accepted
2022-08-08 07:37:47
Documents
13
Period of Report
2022-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tgtx-20220808x8k.htm   iXBRL 8-K 34421
2 EX-99.1 tgtx-20220808xex99d1.htm EX-99.1 168451
  Complete submission text file 0001558370-22-012517.txt   335965

Data Files

Seq Description Document Type Size
3 EX-101.SCH tgtx-20220808.xsd EX-101.SCH 3446
4 EX-101.LAB tgtx-20220808_lab.xml EX-101.LAB 16029
5 EX-101.PRE tgtx-20220808_pre.xml EX-101.PRE 11027
7 EXTRACTED XBRL INSTANCE DOCUMENT tgtx-20220808x8k_htm.xml XML 4780
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

IRS No.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 221142583
SIC: 2834 Pharmaceutical Preparations